Recourse vs. Non-Recourse Patient Financing: Understanding the Trade-Offs
For many healthcare finance leaders, the word recourse triggers an immediate reaction — often not a positive one.
It sounds like retained risk.
It sounds like added complexity.
It sounds like something to avoid.
At the same time, non-recourse patient financing is often viewed as the safer alternative: sell the receivable, receive cash, and move on. The fallacy is that this approach does not eliminate the need for organizations to continually monitor their vendor’s performance and the overall impact on the organization.
But the real decision between recourse and non-recourse models isn’t about one being inherently risky and the other risk-free. In practice, both approaches involve trade-offs that can be measured, managed, and, over time, better understood.
It’s about what trade-offs an organization is willing to make — between certainty and yield, control and convenience, immediacy and long-term value.
Why “recourse” creates hesitation
The concern around recourse is understandable.
Historically, recourse arrangements in finance have implied:
● Unpredictable downside exposure
● Additional reconciliation work, particularly when managing partial repayments and adjustments. This can be minimized by managing the fees as an accounts payable transaction, thus upon placement post the full amount to the patient’s balance.
● Financial risk returning to the balance sheet, requiring ongoing oversight Reserves would be established at the time of placement and since you still own the accounts, they can be re-worked or placed with another vendor. Additionally, you can always end the relationship if you are displeased with the performance
In healthcare — where margins are thin and staffing constraints are real — those concerns are amplified. Leaders want financing options that simplify operations and produce optimal results without introducing new uncertainty.
At the same time, many of these risks are more manageable than they first appear. In well-structured recourse programs, exposure is typically supported by reserves established at placement, helping make outcomes more predictable over time. Operationally, reconciliation can often be streamlined by treating program fees as accounts payable transactions, allowing the full patient balance to remain intact on the Accounts Receivable Trial Balance. And because providers retain ownership of the receivable, they maintain flexibility — including the ability to rework accounts, adjust strategies, or transition to a different partner if needed.
Clear definitions (without the jargon)
Non-recourse patient financing
In a non-recourse model, a healthcare provider sells patient receivables to a financing partner at a deep discount / fee. The provider receives cash up front, and the partner assumes full responsibility for patient repayment — including losses if patients do not pay.
Recourse patient financing
In a recourse model, patient balances are placed into structured payment plans. The provider receives funding at placement but agrees to reimburse the financing partner for a defined portion of balances that ultimately do not complete repayment. Note: there is a discount for the interest paid by the facility and inputted vendor costs and profit.
The real decision: certainty versus retained value
This distinction shows up clearly when looking at the economics.
Non-recourse financing optimizes for:
● Immediate liquidity
● Elimination of downstream variability
● Operational simplicity
Recourse financing optimizes for:
● Higher expected recovery
● Shared performance incentives
● Greater continuity with the patient experience because the vendor operates within your policies and mission statement.
Neither approach is universally “better.” Organizations that have a strong understanding of the underlying value of their accounts receivable — and place less emphasis on maintaining direct influence over the patient financial experience — may lean toward non-recourse for its immediacy. Each model ultimately reflects a different tolerance for trade-offs.
Why patient engagement and factoring of impact on Net Promoter Score changes the equation
Patient behavior plays a much larger role in recourse economics than in non-recourse arrangements.
Clear communication, early outreach, and monthly payment framing all increase the likelihood that patients begin — and continue — making payments. Because recourse models retain more of the receivable’s upside, improvements in engagement directly benefit both the provider and the financing partner.
By contrast, once receivables are sold under non-recourse arrangements, providers typically have limited influence over how patients experience the payment process — even though those experiences can affect brand trust and long-term relationships.
This connection between affordability, engagement, and outcomes is well documented in healthcare finance research and policy analysis, including guidance summarized by the Congressional Research Service in its review of medical debt and payment dynamics.
Operational myths worth challenging
Myth: “Recourse means more work for staff.”
In healthcare-focused recourse programs, patient servicing is typically handled by the financing partner. Reconciliation occurs only for the subset of balances that ultimately default.
Myth: “Non-recourse removes all financial risk.”
Non-recourse removes variability but replaces it with a guaranteed “haircut” that can materially reduce net value of the asset.
Myth: “Patient experience doesn’t affect financial outcomes.”
Multiple healthcare finance analyses — including those shared through the Healthcare Financial Management Association — emphasize that clarity, timing, and trust influence patient payment behavior as much as balance size.
Choosing the right model for your organization
The right financing structure depends on what your organization is optimizing for:
● Relative certainty and optimized liquidity
● Higher retained value over time
● Control over patient communication
● Alignment with community, mission, and system-wide patient experience goals
Some organizations will prioritize certainty and choose non-recourse. Others will accept managed exposure in exchange for higher retained value and greater continuity with patients.
The key takeaway is not that recourse eliminates risk — but that, when thoughtfully designed, it can replace uncertainty with forecasting and planning.
Advanced considerations: learning the true value of your receivables
For some organizations, the decision between recourse and non-recourse is not purely binary — it can also be sequential.
One practical approach is to begin with a recourse-based model to better understand the underlying performance of your patient receivables. Because both the provider and financing partner share in the outcome, this structure can help establish clearer benchmarks around expected yield, patient payment behavior, and the operational realities of managing these balances.
Over time, this creates a more informed view of what those receivables are actually worth — not just in theory, but in practice.
In some cases, organizations use this insight to refine their approach, including reassessing assumptions around discount rates, timing, and overall financial impact. It also allows finance leaders to evaluate how different models affect patient experience, internal workflows, and long-term relationships with the communities they serve.
Rather than viewing recourse solely as a risk decision, this perspective positions it as a tool for gaining clarity — helping organizations make more informed, data-driven choices about how to structure patient financing over time.
Final perspective
Recourse financing shouldn’t be viewed as inherently risky — just as non-recourse financing shouldn’t be viewed as risk-free.
Each model reflects a different philosophy about certainty, value retention, and the role of patient engagement in financial outcomes. For many hospitals and health systems, the conversation today isn’t about avoiding recourse altogether — it’s about understanding whether the economics justify a second look.